jRCTs031210428已完成不适用
Varicella vaccine for patients using TNF-alfa inhibitors
未提供0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 1age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1) Age > 1 year.
- •(2) Patients using TNF-alfa inhibitors
- •(3) Negative or borderline varicella antibody (EIA-IgG < 4.0)
- •(4) CD4 cells > 500/mm3
- •PHA stimulation index > 101.6
- •Serum IgG > 300mg/dL
- •(5) PSL<1mg/day or <2mg/2days
- •(6) Disease activity is stable for more than 6 months.
排除标准
- •(1) Patients using other biological agents.
- •(2) Patients of hematological disease or after bone marrow transplantation.
- •(3) High disease activity.
- •(4) Patients under immunoglobulin replacement.
结局指标
主要结局
-
Presence or absence of vaccine strain varicella
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Efficacy and safety of live varicella vaccine in patients with diabetes mellitus associated with decreased cell-mediated immunity: a Randomized, Double-blind, Placebo-controlled Trialdiabetes mellitusJPRN-UMIN000018879Kitano hospital, The Tazuke Kofukai Medical Research Institute80
招募中
Unknown
Investigation of varicella-zoster vaccine immunogenicity according to frailty statusCertain infectious and parasitic diseasesKCT0009555Seoul National University Bundang Hospital100
尚未招募
不适用
Immunogenic Targets for Therapeutic Vaccination for Liver Cancerprimary liver cancer10019815liver cancerNL-OMON42346Maag Darm Leverziekten, Clinical Research Bureau360
已完成
1 期
Phase I study of a therapeutic vaccine in ATL patients with autologous dendritic cells pulsed with Tax peptidesAdult T cell leukemia/lymphomaJPRN-UMIN000011423ational Hospital Organization Kyushu Cancer Center6
尚未招募
2 期
GcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancerMetastatic hormone-receptor positive and HER2 negative breast cancerBreast NeoplasmsBreast DiseasesRPCEC00000220Center of Molecular Immunology (CIM)286